Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and/or Angiotensin II Receptor Blockers Added to Standard Medical Therapy for Treating Patients With Stable Ischemic Heart Disease and Preserved Left Ventricular Systolic Function

Slide: 16 of 29

Summary of Evaluated Trials That Investigated the Addition of an ACEI or an ARB to Standard Therapy for Stable Ischemic Heart Disease With Preserved Left Ventricular Systolic Function

This table is a brief overview summary of the randomized, placebo-controlled trials that met the inclusion criteria for the comparative effectiveness review (CER). The patients enrolled in these trials had stable ischemic heart disease and preserved left ventricular systolic function and were randomized to receive standard medical therapy alone or standard medical therapy combined with an angiotensin-converting enzyme inhibitor (ACEI) or an angiotensin II receptor blocker (ARB). The enrollment criteria for all of the trials excluded patients who had had a recent myocardial infarction or who had had a revascularization procedure within 3 to 6 months of trial enrollment, depending on the trial.

Of the 9 trials that were evaluated, 7 had investigated ACEIs and two had investigated ARBs. The median follow-up for the trials was 3.5 years (range, 0.5–4.8).

For further details on the trials that were evaluated, please refer to the original CER on which this slide is based (available at: http://effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productID=335).